Diogo Pinto,  —

The U.S. Patent and Trademark Office (USPTO) has issued a new patent to Corbus Pharmaceuticals to cover the use of investigational lenabasum-based therapies for the treatment of fibrotic diseases, including scleroderma. The patent, No. 10,085,964, provides the company exclusive rights for the use of lenabasum-based pharmaceutical compositions…

Specific traits at the time of diagnosis, including symptoms and lung function status, may predict morbidity and mortality in people with scleroderma, a nine-year follow-up study shows. The age and gender of the patient, type of scleroderma, presence of pulmonary fibrosis or hypertension, and lung function status are among…

Magnetic resonance imaging (MRI), a medical technique used to form detailed pictures of the inside of our bodies, has the potential to detect and diagnose abnormalities in the hearts of patients with scleroderma, a study suggests. According to researchers involved in the study, MRI identified abnormalities in the hearts of…

High-intensity exercise of the arms, or arm cranking, may improve blood circulation in scleroderma patients by increasing the dilation of blood vessels (vasodilation) and the amount of oxygen consumed in the muscles, according to researchers. Cycling, an exercise for the legs, also increases muscles’ oxygen consumption, but was not…

Pulmonary arterial hypertension (PAH) represents a major cause of mortality in patients with scleroderma, or systemic sclerosis, accounting for 52% of all deaths — mainly within the first few years after PAH diagnosis, according to recent findings. The fact that PAH is a leading cause of death in scleroderma…

Patients with scleroderma who undergo lung transplants have similar survival rates to patients who get lung transplants due to other diseases, according to a new study. Freedom from chronic lung allograft dysfunction — a set of pathological conditions that cause a transplanted lung to stop breathing — is also similar…